CompaniesStingray Therapeutics

Stingray Therapeutics

active

Houston, TX, United States

Founded 2018

About

Small Molecule

Areas of Focus

Categories

Small Molecule PharmaceuticalSouthwestern U.S.

Clinical Trials (2)

Total Trials

2

As Lead Sponsor

2

As Collaborator

0

Total Enrollment

95

By Phase

PHASE2: 1PHASE1: 1

By Status

RECRUITING: 2

Clinical Trials Pipeline2 trials

Early Phase 1

Phase 1

Phase 2

Phase 3

Phase 4

Phase 1/2

Phase 2/3

N/A

Phase

Status

Role

Condition

2022

2023

2024

2025

2026

2027

2028

Today

Hover over trial bars to see details

Recent Trials

NCT06589440Lead Sponsor

Phase 2 Study of SR-8541A in Combination With Botensilimab and Balstilimab in Subjects With Refractory Metastatic Microsatellite Stable Colorectal Cancer (MSS-CRC)

PHASE2Recruiting

70 participants

Started: Nov 20, 2024 · Completed: Sep 30, 2027

NCT06063681Lead Sponsor

A Study of SR-8541A (ENPPI Inhibitor) in Advanced/Metastatic Solid Tumors

PHASE1Recruiting

25 participants

Started: Oct 12, 2023 · Completed: Dec 31, 2025

Funding History (7)

D

May 14, 2024

D

Feb 2, 2024

D/A

Dec 28, 2023

D

Mar 31, 2023

D/A

May 26, 2021

D/A

Oct 13, 2020

D

Aug 13, 2020

Locations (1)

Headquarters

Houston, TX, United States

Map

Loading map...